SpringWorks Therapeutics presents promising new data on mirdametinib, showing it reduces tumors and improves life for NF1 patients.

SpringWorks Therapeutics will present new data on mirdametinib, a drug for neurofibromatosis type 1-associated tumors, showing significant tumor reduction and improved quality of life for patients. The drug also showed promise in treating pediatric low-grade glioma. The FDA has granted the drug's application for treating NF1-PN a Priority Review, with a decision expected by February 2025.

November 11, 2024
4 Articles